Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGORAC trial of tacrolimus minimization after kidney transplantation
2022-502624-44-00Phase 3Authorised
- Sponsor
- CHU de Nantes
- Start
- Dec 2023
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of tacrolimus in kidney transplant (2 arms), sponsored by CHU de Nantes. Planned start Dec 2023; status: authorised.
02
Drugs
tacrolimus
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2022-502624-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502624-44-00.